Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors

Neuroendocrinology

Volumn 93, Issue 4, 2011, Pages 249-258

  Arnason, Thomas ^a   Sapp, Heidi L ^a   Barnes, Penelope J ^a   Drewniak, Magdalena ^a   Abdolell, Mohamed ^a   Rayson, Daniel ^a,b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Atlantic Clinical Cancer Research Unit   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Carcinoid tumors; Estrogen; HER2 neu; Intestine; Neuroendocrine tumor; Pancreas; Progesterone

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DUODENUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; ILEUM TUMOR; IMMUNOHISTOCHEMISTRY; JEJUNUM TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SMALL INTESTINE TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DUODENAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79959378519     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000326820     Document Type: Article

References (27)

1. Taal BG, Visser O: Epidemiology of neu-roendocrine tumours. Neuroendocrinology 2004; 80(suppl 1):3-7.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hun-dred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
3. Chetty R: An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. Arch Pathol Lab Med 2008; 132: 1285-1289.
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C: World Health Organization Classification of Tumours: Pathology and Genetics-Tu-mours of Endocrine Organs. Lyon, IARC Press, 2004.
5. Kloppel G, Perren A, Heitz PU: The gastro-enteropancreatic neuroendocrine cell sys-tem and its tumors: The WHO classification. Ann NY Acad Sci 2004; 1014: 13-27. (Pubitemid 38594787)
6. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, Mc Nicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wieden-mann B, all other Frascati Consensus Con-ference participants, European NeuroEndocrine Tumor Society (ENETS): TNM staging of foregut (neuro)endocrine tumors: a con-sensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.
7. Rindi G, Kloppel G, Couvelard A, Kommi-noth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a con-sensus proposal including a grading system. Virchows Arch 2007; 451: 757-762. (Pubitemid 47497934)
8. Kloppel G, Couvelard A, Perren A, Kommi-noth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plockinger U, Mallorca Consensus Conference participants, European Neuro-endocrine Tumor Society: ENETS consensus guidelines for the standards of care in neu-roendocrine tumors: towards a standardized approach to the diagnosis of gastroentero-pancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90:162-166.
9. Picard F, Wanatabe M, Schoonjans K, Lydon J, O'Malley BW, Auwerx J: Progesterone re-ceptor knockout mice have an improved glu-cose homeostasis secondary to beta-cell pro-liferation. Proc Natl Acad Sci USA 2002; 99: 15644-15648. (Pubitemid 35403985)
10. Sorenson RL, Brelje TC, Roth C: Effects of steroid and lactogenic hormones on islets of langerhans: A new hypothesis for the role of pregnancy steroids in the adaptation of is-lets to pregnancy. Endocrinology 1993; 133: 2227-2234. (Pubitemid 23324731)
11. Viale G, Doglioni C, Gambacorta M, Zam-boni G, Coggi G, Bordi C: Progesterone re-ceptor immunoreactivity in pancreatic en-docrine tumors-an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer 1992; 70:2268-2277.
12. Pelosi G, Bresaola E, Bogina G, Pasini F, Ro-della S, Castelli P, Iacono C, Serio G, Zam-boni G: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sec-tions is an independent predictor for malig-nancy: a comparative study with proliferat-ing-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27:1124-1134. (Pubitemid 26374929)
13. Hammond ME, Hayes DF, Dowsett M, et al: American society of clinical Oncology/Col-lege of American Pathologists guideline rec-ommendations for immunohistochemical testing of estrogen and progesterone recep-tors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
14. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Ku-likov E, Hill J, Lehle M, Ruschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus che-motherapy alone for treatment of HER2-positive advanced gastric or gastro-oesoph-ageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
15. Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H, Kreipe HH: HER2 diagnostics in gastric can-cer-guideline validation and development of standardized immunohistochemical test-ing. Virchows Arch 2010; 457:299-307.
16. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer 2010; 46: 1949-1959.
17. Evers BM, Rady PL, Tyring SK, Sanchez RL, Rajaraman S, Townsend CM Jr, Thompson JC: Amplification of the HER-2/neu proto-oncogene in human endocrine tumors. Surgery 1992; 112: 211-217, discussion 217-218.
18. Wang DG, Johnston CF, Buchanan KD: On-cogene expression in gastroenteropancreat-ic neuroendocrine tumors: implications for pathogenesis. Cancer 1997; 80:668-675. (Pubitemid 27339821)
19. Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, Jensen RT: Her-2/neu ex-pression and gene amplification in gastri-nomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002; 62: 3702-3710. (Pubitemid 34728850)
20. Yamaguchi M, Hirose K, Hirai N: HER2 ex-pression in gastrointestinal carcinoid tu-mors: High in intestinal but not in gastric tumors. Surg Today 2007; 37: 270-271. (Pubitemid 46365461)
21. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM: Molecular markers for novel therapies in neuroendocrine (carcinoid) tu-mors. Endocr Relat Cancer 2010; 17: 623-636.
22. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, Members of the Cancer Committee, College of American Patholo-gists: Protocol for the examination of speci-mens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 2009; 133: 1515-1538.
23. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145. (Pubitemid 350003059)
24. Moertel CG, Engstrom PF, Schutt AJ: Ta-moxifen therapy for metastatic carcinoid tu-mor: A negative study. Ann Intern Med 1984; 100: 531-532. (Pubitemid 14126747)
25. Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA: Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 2008; 20:1369-1374.
26. Van Eeden S, Quaedvlieg PF, Taal BG, Of-ferhaus GJ, Lamers CB, Van Velthuysen ML: Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 2002; 33:1126-1132. (Pubitemid 35416711)
27. Proca DM, Frankel WL: Pancreatic Endocrine tumors-c-erb B2 (her-2/neu), bcl-2, and p-53 immunohistochemical testing and their value in assessing prognosis. Appl Im-munohistochem Mol Morphol 2008; 16:44-47.